TWiV 845: COVID-19 clinical update #94 with Dr. Daniel Griffin

In COVID-19 clinical update #94, Daniel Griffin reviews the FDA EUA for Paxlovid, test to stay in school, immunity after infection, variants and therapeutics, quarantine and isolation guidelines, Molnupiravir in non-hospitalized patients, and convalescent serum in outpatients. Hosts: Daniel Griffin and Vincent Racaniello Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode FDA EUA for Paxlovid (pdf) Children and COVID-19 (pdf) Evaluation of test to stay in school, IL (MMWR) Evaluation of test to stay in school, LA (MMWR) Update on mRNA vaccine in under 5 yo (Pfizer) CDC endorses preference for mRNA vaccines (CDC) Natural immunity and protection against delta (Clin Inf Dis) Cross-neutralization post-vaccination infection (JAMA) Variants and therapeutics (NIH) Quarantine and isolation (CDC) Molnupiravir in non-hospitalized patients (NEJM) Convalescent serum for outpatients (medRxiv) Letters read on TWiV 845 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkee Send your questions for Dr. Griffin to [email protected]